NeuroPace's Q3 revenue beats estimates

NeuroPace

04/11/2025 21:22

Overview

NeuroPace Q3 revenue of $27.4 mln grows 30%, beating analyst expectations

Gross margin improved to 77.4% due to product mix and efficiencies

Outlook

NeuroPace raises 2025 revenue guidance to $97 mln-$98 mln

Company increases 2025 gross margin guidance to 76%-77%

NeuroPace plans NAUTILUS PMA Supplement submission by year-end 2025

Result Drivers

RNS SYSTEM SALES - Co reports 31% growth in RNS System revenue, driving overall revenue increase

GROSS MARGIN IMPROVEMENT - Favorable product mix and manufacturing efficiencies boosted gross margin to 77.4%

OPERATIONAL MOMENTUM - Submission of Seizure ID™ to FDA and progress on NAUTILUS study contributed to strategic momentum

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$27.35 mln
$24.63 mln (8 Analysts)
Q3 EPS
-$0.11
Q3 Net Income
-$3.49 mln
Q3 Gross Profit
$21.16 mln
Q3 Income from Operations
-$2.60 mln
Q3 Operating Expenses
$23.76 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Neuropace Inc is $18.00, about 47.8% above its November 3 closing price of $9.40

Press Release: ID:nBw1l8Vyva

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)